Papers - YAMAMOTO Hayato
-
The cell surface hyaluronidase TMEM2 regulates cell adhesion and migration via degradation of hyaluronan at focal adhesion sites
Irie F, Tobisawa Y, Murao A, Yamamoto H, Ohyama C, Yamaguchi Y.
JBC 2021.6
-
Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy
Miura H, Hatakeyama S, Tabata R, Fujimori D, Kawashima Y, Moriyama S, Oishi T, Horiguchi H, Soma O, Noro D, Tanaka T, Okamoto T, Yamamoto H, Sato S, Ohyama C.
Multicenter Study 2024.12
-
Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy
Iwamura H, Hatakeyama S, Narita T, Ozaki Y, Konishi S, Horiguchi H, Kodama H, Kojima Y, Fujita N, Okamoto T, Tobisawa Y, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C.
Sci Rep . 2022.1
-
The Cell Surface Hyaluronidase TMEM2 Regulates Cell Adhesion and Migration via Degradation of Hyaluronan at Focal Adhesion Sites
fumitoshi irie, yuki tobisawa, yu yamaguchi
journal of biological chemistry 2021.2
-
TMEM2 expression is downregulated as bladder cancer invades the muscle layer.
Yoneyama MS, Yoneyama T, Tobisawa Y, Yamamoto H, Hatakeyama S, Yoneyama T, Hashimoto Y, Suzuki T, Ohyama C.
Biochem Biophys Res Commun. 2022.7
-
The cell surface hyaluronidase TMEM2 is essential for systemic hyaluronan catabolism and turnover
Tobisawa Y, Fujita N, Yamamoto H, Ohyama C, Irie F, Yamaguchi Y.
JBC 2021.11
-
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer
Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T, Yoneyama F, Hamaya T, Togashi K, Fujita N, Okamoto T, Ohyama C, Hatakeyama S.
cancer med 2024.12
-
Characteristics of α2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level
Yoneyama T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, Hatakeyama S, Narita T, Kodama H, Momota M, Ito H, Narita S, Tsushima F, Mitsuzuka K, Yoneyama T, Hashimoto Y, Duivenvoorden W, Pinthus JH, Kakeda S, Ito A, Tsuchiya N, Habuchi T, Ohyama C.
Prostate. 2021.12
-
Impact of an optimized surveillance protocol based on the European Association of Urology substratification on surveillance costs in patients with primary high-risk non-muscle-invasive bladder cancer
Fujita N, Hatakeyama S, Okita K, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C.
PLoS One. 2023.2
-
Minimum incision endoscopic radical cystectomy in patients with malignant tumors of the urinary bladder: clinical and oncological outcomes at a single institution.
T Koie, C Ohyama, H Yamamoto, S Hatakeyama, S Kudoh, T Yoneyama, Y Hashimoto, N Kamimura
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 38 ( 11 ) 1101 - 1105 2012.11
-
Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study)
Kojima T, Kato R, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Nakaigawa N, Sugino Y, Hamamoto S, Ito H, Murakami H, Obara W.
Observational Study 2022.11
-
Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real-World Multicenter Retrospective Study
Tanaka R, Shinohara M, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Kodama H, Fujita N, Okamoto T, Yamamoto Hayato, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S.
International Journal of Urology 2026.1
-
Integrated Assessment of Percentage α2,3-Linked Sialylated Prostate-specific Antigen and the Prostate Health Index with Magnetic Resonance Imaging for Detection of Clinically Significant Prostate Cancer
Oishi T, Yoneyama T, Miura Y, Hamaya T, Kodama H, Narita T, Mikami J, Fujita N, Okamoto T, Yamamoto Hayato, Imai A, Ohyama C, Hatakeyama S.
Eur Urol Open Sci 2025.12
-
The long-term impact of mild COVID-19 on cardiovascular disease and mortality in patients on hemodialysis: a post-Omicron era retrospective observational study
Okamoto A, Okamoto T, Ichiyama T, Fukushima T, Omizo S, Asanuma H, Sato H, Sakurai H, Yoneyama A, Yoneyama F, Ishii N, Oishi T, Tanaka R, Miura H, Hamaya T, Kodama H, Fujita N, Murasawa H, Yamamoto Hayato, Imai A, Saitoh H, Hatakeyama S, Ohyama C, Suzuki T.
Observational Study 2025.12
-
Immediate Postoperative cfDNA Elevation Predicts Pain After Robot-Assisted Radical Prostatectomy
Noritaka Ishii , Tohru Yoneyama , Satoko Minakawa, Sakae Konishi, Hirotake Kodama, Takuma Narita, Jotaro Mikami, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Atsushi Imai, Chikara Ohyama, Shingo Hatakeyama
2025.11
-
PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Sasaki D, Yoneyama T, Yoneyama F, Ozaki K, Ozaki Y, Miura Y, Fujita N, Okamoto T, Yamamoto Hayato, Goto S, Yoshizawa T, Kurose A, Kijima H, Ohyama C, Hatakeyama S.
International Journal of Urology 2025.9
-
The Effects of the Blood-Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies
Miura H, Hamaya T, Yoneyama T, Shimoyama T, Tsushima F, Togashi K, Miura Y, Yoneyama A, Sato H, Omizo S, Mori K, Kodama H, Fujita N, Okamoto T, Yamamoto Hayato, Kakeda S, Ohyama C, Hatakeyama S.
2025.8
-
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma
Fukushima T, Numakura K, Shinohara M, Kawashima Y, Sekine Y, Mori K, Kobayashi M, Asanuma H, Ichiyama T, Sakurai H, Ozaki K, Fujita N, Okamoto T, Yamamoto Hayato, Yoneyama T, Sato S, Habuchi T, Ohyama C, Hatakeyama S.
Science report 2025.7
-
Serum Serotonin Levels as a Potential Risk Factor for Overactive Bladder in a Community-Dwelling Population: A Four-Year Longitudinal Study
Fukushima T, Okamoto T, Hamaya T, Kodama H, Fujita N, Yamamoto Hayato, Imai A, Nakaji S, Hatakeyama S.
Low Urin Tract Symptoms 2025.7
-
Analytical and Real-World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population
Miura Y, Yoneyama T, Yamamoto Hayato, Suzuki H, Otsubo T, Fujita E, Tsushima F, Goto S, Okamoto T, Fujita N, Ishiyama M, Yoshizawa T, Kakeda S, Hatakeyama S, Ohyama C.
prostate 2025.6